Sarepta Therapeutics, Inc.
US ˙ NasdaqGS ˙ US8036071004

SecuritySRPT / Sarepta Therapeutics, Inc.
InstitutionAlps Advisors Inc
Latest Disclosed Ownership85,469 shares
Latest Disclosed Value $ 1,859,805
Alps Advisors Inc reports 0.66% decrease in ownership of SRPT / Sarepta Therapeutics, Inc.

On May 8, 2026 - Alps Advisors Inc filed a 13F-HR form disclosing ownership of 85,469 shares of Sarepta Therapeutics, Inc. (US:SRPT) valued at $1,859,805 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 86,037 shares of Sarepta Therapeutics, Inc.. This represents a change in shares of -0.66% during the quarter. The current value of the position is $1,388,017 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F SAREPTA THERAPEUTICS COM 803607100 85,469 -568 -0.66 1,860 0.43 0.0080
2026-02-12 2025-12-31 13F SAREPTA THERAPEUTICS COM 803607100 86,037 86,037 1,852 0.0108
2019-02-04 2018-12-31 13F SAREPTA THERAPEU COMMON STOCK 803607100 0 -1,554 -100.00 0 -100.00
2018-10-25 2018-09-30 13F SAREPTA THERAPEU COMMON STOCK 803607100 1,554 -626 -28.72 251 -12.85 0.0016
2018-08-02 2018-06-30 13F/A-2 Sarepta Therapeutics COMMON STOCK 803607100 2,180 -84,505 -97.49 288 -95.52 0.0019
2018-07-31 2018-06-30 13F/A-1 Sarepta Therapeutics COMMON STOCK 803607100 71,619 -15,066 3,985
2018-07-25 2018-06-30 13F Sarepta Therapeutics COMMON STOCK 803607100 71,619 -15,066 3,985
2018-05-01 2018-03-31 13F Sarepta Therapeutics COMMON STOCK 803607100 86,685 15,066 21.04 6,422 61.15 0.0511
2018-02-20 2017-12-31 13F/A-1 Sarepta Therapeutics COMMON STOCK 803607100 71,619 71,619 3,985 0.0276
2018-02-05 2017-12-31 13F Sarepta Therapeutics COMMON STOCK 803607100 71,619 3,985
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.